Alkermes to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two major upcoming investor conferences in March 2025. The company will engage in webcast fireside chats at the TD Cowen 45th Annual Health Care Conference on March 5 at 9:50 a.m. ET and the Leerink Partners Global Healthcare Conference 2025 on March 12 at 11:20 a.m. ET.

The webcasts will be accessible through the Investors tab on Alkermes' website and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with a portfolio including treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations across Ireland, Massachusetts, and Ohio.

News Market Reaction – ALKS

-2.17%

-2.17% Session move

In the trading session that priced this news, ALKS declined 2.17%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences.

TD Cowen 45^th Annual Health Care Conference
Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT)

Leerink Partners Global Healthcare Conference 2025
Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET (3:20 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-upcoming-investor-conferences-302386193.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) presenting at the TD Cowen Healthcare Conference in 2025?

Alkermes will present at the TD Cowen Healthcare Conference on Wednesday, March 5, 2025, at 9:50 a.m. ET (2:50 p.m. GMT).

How can investors access Alkermes (ALKS) conference webcasts in March 2025?

Investors can access the webcasts through the Investors tab on www.alkermes.com. The recordings will be archived for 14 days.

What therapeutic areas does Alkermes (ALKS) focus on in their product portfolio?

Alkermes focuses on neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.

What upcoming conferences will Alkermes (ALKS) participate in during March 2025?

Alkermes will participate in the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025.

Where are Alkermes' (ALKS) main operational locations?

Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.